NCT05629975 (ONSITEMC) is a NA clinical trial of Oral Nutritional Supplements in Nutrition, Healthy, sponsored by Shanghai Tongji Hospital, Tongji University School of Medicine.

Who is sponsoring NCT05629975?

NCT05629975 is sponsored by Shanghai Tongji Hospital, Tongji University School of Medicine.

What drugs are being tested in NCT05629975?

Interventions in NCT05629975: Oral Nutritional Supplements.

What condition does NCT05629975 study?

NCT05629975 studies Nutrition, Healthy.

Is NCT05629975 still recruiting?

NCT05629975 is currently status unknown. Last updated 29 November 2022.

Last reviewed 2022-11-29 · How we verify

NCT05629975: ONSITEMC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Nutritional Supplements in Treatment of Elderly Mild-to-Moderate COVID-19

Status unknown NA Last updated 29 November 2022

What this trial tests

NA trial testing Oral Nutritional Supplements in Nutrition, Healthy in 150 participants. Status unknown.

Timeline

30 November 2022

Primary endpoint
30 December 2022

31 December 2022

Quick facts

Lead sponsor	Shanghai Tongji Hospital, Tongji University School of Medicine
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	150
Start date	30 November 2022
Primary completion	30 December 2022
Estimated completion	31 December 2022

Drugs / interventions tested

Oral Nutritional Supplements

Conditions studied

Nutrition, Healthy — all drugs for Nutrition, Healthy →

Sponsor

Shanghai Tongji Hospital, Tongji University School of Medicine

Who can join

Adults 60 to 90, any sex, with Nutrition, Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The coronavirus disease 2019 (COVID-19) pandemic has seriously threatened public health worldwide. Nutritional supplements may have a positive influence on the recovery of patients with viral infection. This study aimed to assess the influence of oral nutritional supplements (ONSs) on the biochemical parameters of elderly patients with mild-to-moderate COVID-19. This clinical trial will be conducted on 145 elderly patients with mild-to-moderate COVID-19. Patients in the intervention group (n=74) received nutritional powder (vitamins, minerals, dietary fiber, polyphenols, omega-3, amino acids, and probiotics) for 14 days. Cases in the control group (n=71) took the placebo, except for nutritional powder, and they received the same treatment. Biochemical parameters were measured before and two weeks after intervention.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Stand Up to Stand Out: Natural Dietary Polyphenols Curcumin, Resveratrol, and Gossypol as Potential Therapeutic Candidates against Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Wang Z, Song XQ, Xu W, Lei S, et al · · 2023 · cited 12× · PMID 37764669 · DOI 10.3390/nu15183885
Curcumin as an antiviral agent and immune-inflammatory modulator in COVID-19: A scientometric analysis.
Liu K, Zhu Y, Cao X, Liu Y, et al · · 2023 · cited 5× · PMID 38027776 · DOI 10.1016/j.heliyon.2023.e21648

Verify or expand the search:

Other recruiting trials for Nutrition, Healthy

Currently open trials in the same condition.

NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06897982 — Feasibility of a Nutrition Intervention for Patients With Prediabetes at a Federally Qualified Health Center · NA · recruiting
NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
NCT07054294 — Total Energy Expenditure Across the Life Course in Low-and Middle-Income Countries -- Chinese Children · recruiting
NCT07056504 — Technologies and Systems for Assessing Human Energy Metabolism and Nutritional Rehabilitation · recruiting

Other Shanghai Tongji Hospital, Tongji University School of Medicine trials

Trials by the same sponsor.

NCT07384390 — TH-CAR-027 for Grade 4 Gliomas · EARLY_PHASE1 · not yet recruiting
NCT07043218 — A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia · Phase 1 · not yet recruiting
NCT07064109 — Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients · NA · recruiting
NCT06951425 — An Exploratory Clinical Study of the Efficiency and Safety of TH027 in the Treatment of Relapsed/Refractory Solid Tumors · EARLY_PHASE1 · not yet recruiting
NCT06987916 — Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05629975 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Tongji Hospital, Tongji University School of Medicine
Last refreshed: 29 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05629975.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing